$AURA News

Aura Biosciences Announces 108 Patients Enrolled In The Phase 3 Trial Evaluating Belzupacap Sarotalocan As A Frontline Treatment For Patients With Early Choroidal Melanoma; Topline Data Expected In H2 2027

Aura Biosciences Q1 EPS $(0.50) Misses $(0.39) Estimate

Aura Biosciences Prices ~$260.3M Offering Of Common Shares, Pre-Funded Warrants

Aura Plans Share Sale With Option for Additional Stock Purchase

Aura Biosciences Names Natalie Holles as New CEO, Founder Elisabet de los Pinos, Ph.D. Steps Down, Nears Enrollment Completion for Late-Stage Cancer Trial

HC Wainwright & Co. Maintains Buy on Aura Biosciences, Raises Price Target to $24

Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?

Does Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect?

Aura Biosciences, Inc. (AURA) Just Flashed Golden Cross Signal: Do You Buy?

Auranova Announces Closing of Private Placement of Flow-Through Shares

Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year?

Wall Street Analysts Predict a 201.49% Upside in Aura Biosciences (AURA): Here's What You Should Know

Auranova Resources and Kenorland Minerals Commence Spring Drill Program at South Uchi Project

HC Wainwright & Co. Reiterates Buy on Aura Biosciences, Maintains $22 Price Target

Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Aura Biosciences Q4 EPS $(0.37) Beats $(0.45) Estimate

Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?

Auranova Resources and Kenorland Minerals Announce Upcoming 2026 Spring Drill Program at The South Uchi Project, Ontario

Aura Biosciences Eyes Phase 3 Enrollment Milestone, Reaffirms Q4 2027 Melanoma Data Timeline

Aura Biosciences Touts Phase 3 bel-sar Momentum, Eyes Mid-Year Bladder Cancer Data at TD Cowen Conference